Actinium Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ATNM) $4.18 +0.16 (+3.98%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$4.02▼$4.2550-Day Range$7.12▼$14.2652-Week Range$4.00▼$14.70Volume136,963 shsAverage Volume261,712 shsMarket Capitalization$114.57 millionP/E RatioN/ADividend YieldN/APrice Target$27.15 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Actinium Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside549.5% Upside$27.15 Price TargetShort InterestHealthy6.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.03) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.4 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.15, Actinium Pharmaceuticals has a forecasted upside of 549.5% from its current price of $4.18.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.75% of the outstanding shares of Actinium Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverActinium Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Actinium Pharmaceuticals has recently decreased by 7.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 3.1 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search Interest12 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows5 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.38% of the stock of Actinium Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.Read More ATNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesNovember 27, 2023 | msn.comCadila Pharmaceuticals inaugurates Rs 200-crore API plant in Dahej, aims to expand to new marketsNovember 21, 2023 | americanbankingnews.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Sell at StockNews.comNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | finance.yahoo.comActinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsNovember 5, 2023 | markets.businessinsider.comPromising Iomab-B Therapy Results and Sound Financial Standing Bolster Buy Rating for Actinium PharmaceuticalsNovember 3, 2023 | seekingalpha.comActinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A BuyNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), Sotera Health (SHC) and Elevation Oncology (ELEV)November 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Actinium Pharmaceuticals (ATNM) and QuidelOrtho (QDEL)November 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 2, 2023 | finance.yahoo.comActinium Pharmaceuticals to Attend Bio-Europe Munich 2023November 2, 2023 | finance.yahoo.comActinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialOctober 31, 2023 | finance.yahoo.comNeurocrine Biosciences (NBIX) Q3 Earnings Miss EstimatesOctober 4, 2023 | finance.yahoo.comActinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyOctober 4, 2023 | msn.comB. Riley Securities Reiterates Actinium Pharmaceuticals (ATNM) Buy RecommendationOctober 3, 2023 | markets.businessinsider.comPromising Future for Actinium Pharmaceuticals: Potential Acquisition Target and Progress towards CommercializationSeptember 27, 2023 | finance.yahoo.comActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingSeptember 23, 2023 | finance.yahoo.comActinium to Host Key Opinion Leader Event Focused on Bone Marrow Transplant, Potential Role of Iomab-B on May 12September 15, 2023 | msn.comActinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?September 10, 2023 | msn.comHSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on GileadSeptember 7, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Inovio Pharmaceuticals (INO)September 7, 2023 | finance.yahoo.comActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOSeptember 7, 2023 | msn.comHSBC Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Buy RecommendationSeptember 1, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)August 31, 2023 | finance.yahoo.comActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAugust 21, 2023 | finance.yahoo.comActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressAugust 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)August 15, 2023 | msn.comHC Wainwright & Co. Maintains Actinium Pharmaceuticals (ATNM) Buy RecommendationSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$27.15 High Stock Price Target$50.00 Low Stock Price Target$11.60 Potential Upside/Downside+549.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,020,000.00 Net MarginsN/A Pretax Margin-102,975.55% Return on Equity-91.02% Return on Assets-49.62% Debt Debt-to-Equity RatioN/A Current Ratio9.87 Quick Ratio9.87 Sales & Book Value Annual Sales$1.03 million Price / Sales111.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.63Miscellaneous Outstanding Shares27,410,000Free Float26,316,000Market Cap$114.57 million OptionableNot Optionable Beta0.31 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Sandesh C. Seth M.B.A. (Age 59)M.S., Chairman & CEO Comp: $1.15MMr. Steven O'Loughlin BS (Age 37)CFO & Corporate Secretary Comp: $585kDr. Paul Diamond Esq.Ph.D., Vice President of Patent & Legal CounselDr. David GouldSenior Vice President of Corporate Development & Corporate AffairsDr. Bernie Cunningham P.M.P.Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing LiangVP & Head of Radiation SciencesDr. Avinash Desai M.D.Chief Medical OfficerMs. Jenny HsiehChief Strategy OfficerMs. Sunitha LakshminarayananSenior VP, Head of CMC & Product DevelopmentMs. Elaina HaeuberVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYProQR TherapeuticsNASDAQ:PRQRPepGenNASDAQ:PEPGNewron PharmaceuticalsOTCMKTS:NWPHFEagle PharmaceuticalsNASDAQ:EGRXView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 13,265 shares on 11/24/2023Ownership: 0.056%California State Teachers Retirement SystemSold 2,762 shares on 11/14/2023Ownership: 0.021%Brandywine Global Investment Management LLCBought 174,500 shares on 11/13/2023Ownership: 0.637%Invesco Ltd.Bought 20,500 shares on 11/13/2023Ownership: 0.123%UBS Group AGBought 12,163 shares on 11/9/2023Ownership: 0.044%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks. What is Actinium Pharmaceuticals' stock price target for 2024? 4 Wall Street analysts have issued twelve-month price targets for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's stock price to reach $27.15 in the next twelve months. This suggests a possible upside of 549.5% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts. How have ATNM shares performed in 2023? Actinium Pharmaceuticals' stock was trading at $10.65 at the start of the year. Since then, ATNM stock has decreased by 60.8% and is now trading at $4.18. View the best growth stocks for 2023 here. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,850,000 shares, a decrease of 7.5% from the October 31st total of 2,000,000 shares. Based on an average trading volume of 190,100 shares, the days-to-cover ratio is currently 9.7 days. View Actinium Pharmaceuticals' Short Interest. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.01. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Brandywine Global Investment Management LLC (0.64%), Charles Schwab Investment Management Inc. (0.28%), Invesco Ltd. (0.12%), Deutsche Bank AG (0.06%), Deutsche Bank AG (0.06%) and UBS Group AG (0.04%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:ATNM) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.